In addition to Drs. Fraser, Cullis and Mr. Nixon, the following professionals are corporate directors of Molecular You.
Paul is President and CEO of PHEMI, and serves on the Board of Directors for Providence Health Care, advising on its subcommittees for innovation, quality, EMR, and next-generation data strategies in healthcare. Paul also serves on the Board of Directors for Life Sciences BC and is an advisor to the BC provincial government. He is an adjunct professor in big data at Simon Fraser University and is a partner with Magellan Angel Partners. He is a member of the BC Institute for Health Innovation and serves on Genome BC’s Health Strategy Task Force. Paul is also an Ambassador for Privacy by Design. Paul spent over a decade as the secretary/treasurer & technology adviser for the Michael Smith Foundation for Health Research, British Columbia’s health research support agency, and was one of the Entrepreneurs-in-Residence at SFU Venture Labs. Prior to his experience in healthcare and venture capital, Paul was the CTO and cofounder of OctigaBay Systems – a pioneer in high-performance computing – which was acquired by Cray Inc., the world leader in supercomputing. He was also the cofounder and CTO of Abatis Systems, which was acquired by Redback Networks in one of the largest technology acquisitions in Canadian history. Paul’s early career included senior roles at Newbridge Networks and at technology companies in the UK. Paul was awarded Canada’s “Top 40 Under 40′′ award in 2000. He holds an MBA from the Cranfield School of Management, a marketing diploma from the Chartered Institute of Marketing, a PhD in Electrical Engineering and an honours Bachelor’s degree from the University of Liverpool.
Bruce is Professor, Pathology and Laboratory Medicine, UBC, CEO, the Centre of Excellence for Prevention of Organ Failure (PROOF Centre) www.proofcentre.ca and Co-Director, Institute for Heart + Lung Health www.heartandlung.ca. Dr. McManus has an extensive background in clinical medicine and molecular sciences, especially related to inflammatory and infectious disorders of heart, lung and blood vessels. He served as the inaugural Scientific Director, Institute of Circulatory & Respiratory Health, and Canadian Institutes of Health Research. He has convened many public-private partnerships; he has mentored large numbers of students and trainees. His passion for development of omics-derived bio-signatures to augment clinical laboratory medicine & drug development processes in industry is enabled by a longstanding connection to computational and systems sciences. He has co-authored 400 full- length, peer-reviewed papers in biomedicine, co-holds several patents & has co-founded several companies.